These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 1349276)

  • 1. [Glutamic acid antagonists as antiparkinson agents?].
    Schmidt WJ
    Dtsch Med Wochenschr; 1992 Apr; 117(17):682-3. PubMed ID: 1349276
    [No Abstract]   [Full Text] [Related]  

  • 2. Recent advances in pharmacological therapy of Parkinson's disease.
    Riederer P; Lange KW; Youdim MB
    Adv Neurol; 1993; 60():626-35. PubMed ID: 8093582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of glutamate in the pathophysiology of Parkinson's disease.
    Blandini F; Greenamyre JT; Nappi G
    Funct Neurol; 1996; 11(1):3-15. PubMed ID: 8936453
    [No Abstract]   [Full Text] [Related]  

  • 4. Parkinson disease.
    Friedman JH
    N Y State J Med; 1987 Mar; 87(3):139-40. PubMed ID: 3472108
    [No Abstract]   [Full Text] [Related]  

  • 5. Amantadine and other antiglutamate agents: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S13-22. PubMed ID: 12211136
    [No Abstract]   [Full Text] [Related]  

  • 6. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
    Olanow CW; Mytilineou C; Tatton W
    Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720
    [No Abstract]   [Full Text] [Related]  

  • 7. Preclinical versus clinical neuroprotection.
    Grünblatt E; Schlösser R; Gerlach M; Riederer P
    Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of amphetamine induced stereotyped behaviour as a model for the experimental evaluation of antiparkinson agents.
    Costall B; Naylor RJ; Wright T
    Arzneimittelforschung; 1972 Jul; 22(7):1178-83. PubMed ID: 4404343
    [No Abstract]   [Full Text] [Related]  

  • 9. Levodopa in the treatment of Parkinson's disease: current controversies.
    Gerlach M; Reichmann H; Riederer P
    Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
    [No Abstract]   [Full Text] [Related]  

  • 10. Special focus section: gene therapy for Parkinson's disease.
    Fiske BK; Frasier MA; Sherer TB
    Exp Neurol; 2008 Jan; 209(1):28-9. PubMed ID: 17980867
    [No Abstract]   [Full Text] [Related]  

  • 11. [Drug information: antiparkinson agents].
    Veje JO
    Sygeplejersken; 1981 Aug; 81(32):10. PubMed ID: 6913211
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibitors of dopamine inactivating systems as antiparkinson drugs.
    Youdim MB
    Adv Neurol; 1990; 53():483-8. PubMed ID: 2239488
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapeutic effectiveness of modern antiparkinson agents].
    Kurako IuL; Volianskiĭ VE; Fadeev SM
    Vrach Delo; 1981 Feb; (2):7-11. PubMed ID: 7222616
    [No Abstract]   [Full Text] [Related]  

  • 14. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease.
    Starr MS
    Synapse; 1995 Apr; 19(4):264-93. PubMed ID: 7792721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on Parkinson disease.
    Lieberman AN
    N Y State J Med; 1987 Mar; 87(3):147-53. PubMed ID: 3472111
    [No Abstract]   [Full Text] [Related]  

  • 16. [Drug therapy of Parkinson disease].
    Schneider E
    Med Monatsschr Pharm; 2000 Apr; 23(4):116-24. PubMed ID: 10812899
    [No Abstract]   [Full Text] [Related]  

  • 17. [The effectiveness of the use of new types of antiparkinson agents].
    Federmann J; Honzáková L; Roth B; Stika L
    Cesk Zdrav; 1981 Jun; 29(6):229-41. PubMed ID: 7261170
    [No Abstract]   [Full Text] [Related]  

  • 18. New drugs in the treatment of Parkinson's disease. An introduction.
    Bracco F
    Adv Neurol; 1996; 69():513-7. PubMed ID: 8615173
    [No Abstract]   [Full Text] [Related]  

  • 19. Renaissance of amantadine in the treatment of Parkinson's disease.
    Blanchet PJ; Metman LV; Chase TN
    Adv Neurol; 2003; 91():251-7. PubMed ID: 12442683
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiparkinsonian activity of adenosine A2A antagonists in experimental models.
    Kuwana Y; Shiozaki S; Kanda T; Kurokawa M; Koga K; Ochi M; Ikeda K; Kase H; Jackson MJ; Smith LA; Pearce RK; Jenner PG
    Adv Neurol; 1999; 80():121-3. PubMed ID: 10410710
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.